Burning Rock Biotech (BNR) Projected to Announce Quarterly Earnings on Wednesday

Burning Rock Biotech (NASDAQ:BNR) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, September 2nd. Analysts expect Burning Rock Biotech to post earnings of ($2.2883) per share and revenue of $19.2060 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, September 8, 2026 at 12:30 PM ET.

Burning Rock Biotech (NASDAQ:BNR) last announced its earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($2.29) by $2.09. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%. The company had revenue of $15.66 million during the quarter, compared to the consensus estimate of $19.21 million.

Burning Rock Biotech Stock Down 7.3%

BNR opened at $9.45 on Tuesday. Burning Rock Biotech has a fifty-two week low of $6.79 and a fifty-two week high of $41.72. The firm has a market capitalization of $99.41 million, a P/E ratio of -11.52 and a beta of 1.34. The company’s 50-day moving average is $9.53 and its 200 day moving average is $14.92. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.05 and a quick ratio of 2.81.

Analyst Ratings Changes

BNR has been the subject of several analyst reports. Wall Street Zen lowered shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings downgraded Burning Rock Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Insider Activity

In other Burning Rock Biotech news, Director Yusheng Han bought 24,900 shares of the stock in a transaction dated Friday, June 26th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $199,200.00. Following the purchase, the director directly owned 18,404,086 shares of the company’s stock, valued at approximately $147,232,688. This trade represents a 0.14% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders acquired 731,410 shares of company stock worth $6,182,660. Company insiders own 30.30% of the company’s stock.

Hedge Funds Weigh In On Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. Marshall Wace LLP acquired a new position in shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned about 0.10% of Burning Rock Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.